ResMed share price jumps 10% on strong quarterly update

ResMed has impressed the market with its third-quarter update.

| More on:
A smiling businessman in the city looks at his phone and punches the air in celebration of good news.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The ResMed Inc (ASX: RMD) share price is avoiding the market selloff and racing higher on Friday.

In early trade, the sleep disorder treatment company's shares are up an impressive 10% to $31.50.

This compares favourably to a 0.8% decline by the ASX 200 index this morning.

Why is the ResMed share price jumping?

Investors have been fighting to get hold of the company's shares this morning following the release of its third-quarter update.

According to the release, ResMed reported a 7% increase in revenue to US$1.2 billion for the three months ended 31 March. This was driven by increased demand for sleep devices, as well as strong growth across its mask product portfolio.

United States, Canada, and Latin America revenue grew by 9%, Europe, Asia, and other markets revenue rose 3%, and software-as-a-service revenue increased by 8%.

Another big positive was the company's gross margin, which improved 260 basis points to 57.9% on a GAAP basis and 240 basis points to 58.5% on a non-GAAP basis. This was ahead of the consensus estimate for a gross margin of 57.6%.

This led to income from operations increasing 25% for the quarter to US$374.6 million and diluted earnings per share lifting 29% to US$2.04 per share.

A quarterly dividend of US$0.48 per share was declared. Though, it is worth noting that this equates to 4.8 US cents for ResMed's ASX-listed shares.

Management commentary

ResMed's chairman and CEO, Mick Farrell, was rightfully pleased with the company's performance during the quarter. He said:

ResMed's strong third-quarter fiscal year 2024 results reflect robust patient and customer demand for our products and software solutions, leading to double-digit mask and accessories revenue growth along with ongoing operational efficiencies to drive margin improvement and increased profitability, resulting in double-digit growth in both operating profit and earnings per share.

Farrell also spoke positively about the company's long-term outlook, highlighting its huge market opportunity. It said:

Over 2 billion people worldwide can benefit from a ResMed solution to help them sleep better, breathe better, and receive best-in-class healthcare right where they live. We remain laser-focused on bringing market-leading innovation to customers, including our latest AirCurve11 range of non-invasive ventilators and our recently launched AirFit F40 mask system, combined with our entire portfolio of products, software, and solutions, allowing us to continue to deliver value for all our stakeholders.

Following this gain, the ResMed share price is now up almost 24% in 2024.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Why CSL shares could be a bargain buy at $240

Let's see what Bell Potter is saying about this blue chip.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »